We are live on ! Find out more
EVGN icon

Evogene
EVGN

17 hedge funds and large institutions have $12M invested in Evogene in 2020 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 1

100% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 2

11% more capital invested

Capital invested by funds: $10.8M → $12M (+$1.23M)

6% more funds holding

Funds holding: 16 → 17 (+1)

2.24% more ownership

Funds ownership: 26.16% → 28.4% (+2.2%)

Holders
17
Holders Change
+1
Holders Change %
+6.25%
% of All Funds
0.37%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
4
Reduced
2
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CI
Clal Insurance
Israel
+$813K
2
AIM
ARK Investment Management
Florida
+$39.8K
3
Goldman Sachs
Goldman Sachs
New York
+$37.2K
4
Jane Street
Jane Street
New York
+$26.7K
5
Wells Fargo
Wells Fargo
California
+$23.4K

Top Sellers

Rank Fund Capital Flow
1
MCM
Moon Capital Management
New York
-$117K
2
UBS Group
UBS Group
Switzerland
-$18.7K
3
Citigroup
Citigroup
New York
-$12K

EVGN Hedge Fund Activity: Q1 2020 in Review

17 of the 4,548 institutional investors tracked by Wall St. Rank reported a position in Evogene (EVGN) for Q1 2020, worth a combined $12M — up 11% from $10.8M a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new EVGN positions and 1 closed out — a net gain of 1 holder — while 4 added to existing stakes and 2 trimmed.

The largest buyer was Clal Insurance, adding an estimated $813K. The largest seller was Moon Capital Management, cutting an estimated $117K.

  • 17 institutional investors held Evogene (EVGN) as of Q1 2020, up from 16 in Q4 2019.
  • Funds reported $12M of Evogene stock for Q1 2020, up 11% quarter-over-quarter.
  • 2 funds opened new Evogene positions in Q1 2020 and 1 closed out, a net change of +1 holder.
  • The largest Evogene buyer in Q1 2020 was Clal Insurance, an estimated $813K added.
  • The largest Evogene seller in Q1 2020 was Moon Capital Management, an estimated $117K sold.

Based on aggregated 13F filings for Q1 2020.